The FDA approved a new strength of a trastuzumab biosimilar; UnitedHealth will remove reference adalimumab from some ...
Number 3: Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is ...
In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in ...
A summary of research written by Vibeke Strand, MD, clinical professor in division of immunology/rheumatology at Stanford ...
Otulfi was approved simultaneously in the European Union. In the US, it will launch in February 2025.
Ivo Abraham, PhD, RN, University of Arizona Cancer Center, explains how biosimilars are becoming more accessible but face challenges like price erosion and potential shortages.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback